A significant proportion of clinically at-risk patients with certain immunocompromised or immunosuppressed conditions mount a low or undetectable immune response after two doses of the same COVID-19 vaccine
Professor Pam Kearns, Director of the Institute of Cancer and Genomic Sciences, writes an opinion piece on how COVID-19 has replaced cancer as 'the big C'.
A new and less invasive treatment developed by researchers is safer than standard major surgery for early-stage rectal cancer, giving patients a better quality of life with fewer life-altering side effects.
The first national study of children with cancer who test positive from COVID-19 has found that they are not at any increased risk of severe COVID-19 infection.
A new study from the University of Birmingham has found that 50% of patients with a rare type of cancer that has spread into the lining of their abdomen may be suitable for immunotherapy treatment.
A new research centre which aims to overcome barriers for a common, but often overlooked cancer has opened at the University of Birmingham.
A newly published study led by the Universities of Oxford and Birmingham has found that, compared to other cancers, patients with blood cancers are more vulnerable to the effects of the coronavirus pandemic.
A pioneering lung cancer study has highlighted important factors that will need to be considered in the next wave of precision medicine studies particularly in treating genomically complicated cancers.
During this period of uncertainty, we spoke to some of our researchers in a series of blog posts to find out what it's like to be a scientist and working from home.
A new study led by the Universities of Birmingham and Oxford has found the mortality rate in cancer patients who are assessed or treated in hospital with COVID-19 is not significantly affected by anti-cancer treatments.
A clinical trial from the University of Birmingham has found that a new group of patients with lung cancer could benefit from immunotherapy treatment.
Sarcoma UK: Professor Andrew Beggs hopes to use the DNA of cancer cells to answer a very pressing question – why don't sarcomas respond well to immunotherapy?